Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
131 hedge funds and large institutions have $829M invested in Intra-Cellular Therapies Inc. in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 47 reducing their positions, and 19 closing their positions.
50% more capital invested
Capital invested by funds: $553M → $829M (+$276M)
47% more call options, than puts
Call options by funds: $30.8M | Put options by funds: $21M
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
0% more funds holding
Funds holding: 131 → 131 (0)
13% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 47
Top Buyers
| 1 |
PC
PointState Capital
New York
|
+$36.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18.9M |
| 4 |
DFO
Duquesne Family Office
New York
|
+$5.79M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.69M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$17.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$8.82M |
| 3 |
SC
Samlyn Capital
New York
|
-$6.83M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$5.69M |
| 5 |
BlackRock
New York
|
-$4.87M |
ITCI Hedge Fund Activity: Q1 2018 in Review
131 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2018, worth a combined $829M — up 50% from $553M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ITCI positions and 19 closed out — a net gain of 1 holder — while 41 added to existing stakes and 47 trimmed.
The largest buyer was PointState Capital, opening a new position worth an estimated $36.4M. The largest seller was Millennium Management, cutting an estimated $17.2M.
- 131 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $829M of Intra-Cellular Therapies Inc. stock for Q1 2018, up 50% quarter-over-quarter.
- 20 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2018 and 19 closed out, a net change of +1 holder.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2018 was PointState Capital, an estimated $36.4M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2018 was Millennium Management, an estimated $17.2M sold.
Based on aggregated 13F filings for Q1 2018.